Molecular Therapy - Nucleic Acids

Slides:



Advertisements
Similar presentations
Molecular Therapy - Oncolytics
Advertisements

Molecular Therapy - Nucleic Acids
Factor VII-Induced MicroRNA-135a Inhibits Autophagy and Is Associated with Poor Prognosis in Hepatocellular Carcinoma  Kuang-Tzu Huang, I-Ying Kuo, Ming-Chao.
Integrin αvβ6 Promotes Lung Cancer Proliferation and Metastasis through Upregulation of IL-8–Mediated MAPK/ERK Signaling  Pengwei Yan, Huanfeng Zhu, Li.
Volume 15, Issue 6, Pages (June 2012)
The ER-Mitochondria Tethering Complex VAPB-PTPIP51 Regulates Autophagy
RhoD Inhibits RhoC-ROCK-Dependent Cell Contraction via PAK6
Volume 137, Issue 2, Pages e2 (August 2009)
Volume 142, Issue 4, Pages (April 2012)
Therapeutic Suppression of miR-4261 Attenuates Colorectal Cancer by Targeting MCC  Guanming Jiao, Qi Huang, Muren Hu, Xuchun Liang, Fuchen Li, Chunling.
Volume 21, Issue 12, Pages (December 2017)
CaMKII inhibition in human primary and pluripotent stem cell-derived chondrocytes modulates effects of TGFβ and BMP through SMAD signaling  B. Saitta,
UCHL1 Regulates Melanogenesis through Controlling MITF Stability in Human Melanocytes  Eun Young Seo, Seon-Pil Jin, Kyung-Cheol Sohn, Chi-Hyun Park, Dong.
Molecular Therapy - Nucleic Acids
Complete Cure of Persistent Virus Infections by Antiviral siRNAs
Volume 110, Issue 11, Pages (June 2016)
Volume 20, Issue 7, Pages (August 2017)
Volume 17, Issue 12, Pages (December 2009)
Alice C.L. Len, Shimona Starling, Maitreyi Shivkumar, Clare Jolly 
Tyrosinase-Based Reporter Gene for Photoacoustic Imaging of MicroRNA-9 Regulated by DNA Methylation in Living Subjects  Haifeng Zheng, Lin Zhou, Yaru.
Volume 15, Issue 4, Pages (April 2014)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Inhibition of KLF4 by Statins Reverses Adriamycin-Induced Metastasis and Cancer Stemness in Osteosarcoma Cells  Yangling Li, Miao Xian, Bo Yang, Meidan.
Volume 23, Issue 10, Pages (October 2015)
Volume 24, Issue 11, Pages e3 (September 2018)
Volume 23, Issue 7, Pages (May 2018)
Molecular Mechanisms Regulating the Defects in Fragile X Syndrome Neurons Derived from Human Pluripotent Stem Cells  Tomer Halevy, Christian Czech, Nissim.
Hemagglutinin-targeting Artificial MicroRNAs Expressed by Adenovirus Protect Mice From Different Clades of H5N1 Infection  Xinying Tang, Hongbo Zhang,
Volume 22, Issue 1, Pages e7 (July 2017)
Ribosomal Protein S3 Gene Silencing Protects Against Cigarette Smoke-Induced Acute Lung Injury  Jinrui Dong, Wupeng Liao, Hong Yong Peh, W.S. Daniel Tan,
Alexander Falkenhagen, Sadhna Joshi  Molecular Therapy - Nucleic Acids 
Volume 21, Issue 2, Pages (February 2013)
Volume 6, Issue 6, Pages (March 2014)
Volume 9, Issue 9, Pages (September 2016)
Volume 138, Issue 7, Pages e1 (June 2010)
Volume 9, Issue 5, Pages (November 2017)
Volume 39, Issue 3, Pages (August 2010)
CD46 Is a Cellular Receptor for Human Herpesvirus 6
Volume 13, Issue 4, Pages (April 2013)
Molecular Therapy - Nucleic Acids
Volume 18, Issue 6, Pages (December 2015)
Shrimp miR-34 from Shrimp Stress Response to Virus Infection Suppresses Tumorigenesis of Breast Cancer  Yalei Cui, Xiaoyuan Yang, Xiaobo Zhang  Molecular.
Urtzi Garaigorta, Francis V. Chisari  Cell Host & Microbe 
Cellular 5′-3′ mRNA Exonuclease Xrn1 Controls Double-Stranded RNA Accumulation and Anti-Viral Responses  Hannah M. Burgess, Ian Mohr  Cell Host & Microbe 
Emma Abernathy, Sarah Gilbertson, Ravi Alla, Britt Glaunsinger 
Diverse Herpesvirus MicroRNAs Target the Stress-Induced Immune Ligand MICB to Escape Recognition by Natural Killer Cells  Daphna Nachmani, Noam Stern-Ginossar,
Dan Yu, Rongdiao Liu, Geng Yang, Qiang Zhou  Cell Reports 
Long Noncoding RNA BC as a Novel Therapeutic Target for Colorectal Cancer that Suppresses Metastasis by Upregulating TIMP3  Jiaxin Lin, Xin Tan,
Volume 12, Issue 10, Pages (September 2015)
MELK Promotes Melanoma Growth by Stimulating the NF-κB Pathway
Negative Regulation of Tumor Suppressor p53 by MicroRNA miR-504
Volume 6, Issue 3, Pages (March 2016)
Rational Design of Therapeutic siRNAs: Minimizing Off-targeting Potential to Improve the Safety of RNAi Therapy for Huntington's Disease  Ryan L Boudreau,
Molecular Therapy - Nucleic Acids
Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia  Raquel Vinhas, Alexandra R.
Volume 17, Issue 3, Pages (October 2016)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
KIF13A depletion leads to a drop in virus titers, without affecting viral protein expression. KIF13A depletion leadsto a drop in virus titers, without.
The Expression of MicroRNA-598 Inhibits Ovarian Cancer Cell Proliferation and Metastasis by Targeting URI  Feng Xing, Shuo Wang, Jianhong Zhou  Molecular.
Volume 15, Issue 4, Pages (April 2014)
Volume 26, Issue 10, Pages (October 2018)
Volume 23, Issue 4, Pages (April 2015)
Volume 27, Issue 11, Pages e4 (June 2019)
Circular RNA Transcriptomic Analysis of Primary Human Brain Microvascular Endothelial Cells Infected with Meningitic Escherichia coli  Ruicheng Yang,
Role of Cell-Penetrating Peptides in Intracellular Delivery of Peptide Nucleic Acids Targeting Hepadnaviral Replication  Bénédicte Ndeboko, Narayan Ramamurthy,
Genome Editing Reveals Glioblastoma Addiction to MicroRNA-10b
Volume 26, Issue 9, Pages e5 (September 2019)
Presentation transcript:

Molecular Therapy - Nucleic Acids Broad-Spectrum Inhibition of Respiratory Virus Infection by MicroRNA Mimics Targeting p38 MAPK Signaling  Jana L. McCaskill, Sarah Ressel, Andreas Alber, Jane Redford, Ultan F. Power, Jürgen Schwarze, Bernadette M. Dutia, Amy H. Buck  Molecular Therapy - Nucleic Acids  Volume 7, Pages 256-266 (June 2017) DOI: 10.1016/j.omtn.2017.03.008 Copyright © 2017 The Authors Terms and Conditions

Figure 1 Reductions in IAV and RSV Titer following Treatments with miRNA Mimics A549 cells were transfected with 25 nM miRNA mimics or controls. A direct-targeting viral siRNA (siIAV or siRSV) served as a positive antiviral control (gray bar), while negative controls were as follows: C. elegans miRNA mimic 1 (C.elegans 1), RISC-free siRNA, Lipofectamine, and virus infection alone (black bars). (A–E) After 48-hr transfection, media was removed and cells were infected with (A) IAV WSN H1N1 at MOI 0.1 for 24 hr, (B) IAV PR8 H1N1 at MOI 0.1 for 12 hr, (C) IAV Udorn H3N2 at MOI 0.1 for 24 hr, (D) RSV-A2 at MOI 0.01 for 72 hr, and (E) RSV-BT2a at MOI 0.1 for 72 hr, when the supernatant was removed and assayed for virus. (F) Uninfected cells were analyzed for cell viability at 48 hr post-transfection (n = 12). The results are displayed to show the most potent antiviral mimics (from left to right along the x axis), with solid lines denoting 0% inhibition, dotted lines denoting the 75% activity cutoff, and blue bars highlighting miRNAs chosen for further analysis. Viral titer results for each virus are shown as the mean ± SEM of n = 6. Significant differences between virus control and miRNA mimics and siRNAs are indicated (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001, one-way ANOVA). Molecular Therapy - Nucleic Acids 2017 7, 256-266DOI: (10.1016/j.omtn.2017.03.008) Copyright © 2017 The Authors Terms and Conditions

Figure 2 Analysis of Changes in Global Pathway Signaling Molecules upon Infection or miRNA Transfection (A) Venn diagram of RPPA markers in untransfected cells whose levels were increased or decreased by >25% upon infection when compared to the uninfected average. (B) Cells were transfected with 25 nM miRNA mimics or controls and subsequently infected with IAV WSN at MOI 3. Heatmap shows protein levels analyzed by RPPA at 24 hpi, normalized to RISC-free siRNA treatment. Hierarchical clustering was conducted with Pearson correlation. (C and D) Relative fluorescence intensity of (C) total p-p38 MAPK + p38 MAPK or (D) MAPKAPK2 protein levels from RPPA examination is shown as the mean ± SEM of n = 2. Molecular Therapy - Nucleic Acids 2017 7, 256-266DOI: (10.1016/j.omtn.2017.03.008) Copyright © 2017 The Authors Terms and Conditions

Figure 3 Validation of p38 MAPK Pathway Downregulation by Antiviral miRNA Mimics (A) p38 MAPK-signaling pathway including kinases, transcription factors, and other genes induced or activated by p38 stimuli. (B) Western blot analysis of p38 MAPK pathway mediators in A549 cells that were transfected with 10 nM miRNA mimics, 25 nM inhibitors, or controls and subsequently infected with IAV WSN at MOI 3 for 24 hr. (C–G) Quantitative analysis of (C) p-p38 MAPK, (D) p38 MAPK, (E) MK2, (F) pHsp27, and (G) Myc total protein levels normalized to GAPDH shown as the mean ± SEM of n = 4. (H) Summary of quantitative analysis with X denoting significant downregulation. Significant differences between RISC-free siRNA control and miRNA mimics and inhibitors are indicated (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001, one-way ANOVA). Molecular Therapy - Nucleic Acids 2017 7, 256-266DOI: (10.1016/j.omtn.2017.03.008) Copyright © 2017 The Authors Terms and Conditions

Figure 4 Role of MK2 Suppression in IAV Infection (A) Representative western blot analysis of MK2 and MK3 expression in A549 cells transfected with 10 nM miRNA mimics, siMK2, siMK3, or controls for 48 hr. Cells were subsequently infected with IAV WSN at MOI 3 for 24 hr. (B and C) Quantitative analysis of (B) MK2 or (C) MK3 total protein levels during IAV infection normalized to GAPDH shown as the mean ± SEM of n = 4. (D) IAV viral titer is shown as the mean ± SEM of n = 4. Significant differences between RISC-free siRNA control and miRNA or siRNA treatments are indicated (*p < 0.05, **p < 0.01, and ****p < 0.0001, one-way ANOVA). Molecular Therapy - Nucleic Acids 2017 7, 256-266DOI: (10.1016/j.omtn.2017.03.008) Copyright © 2017 The Authors Terms and Conditions

Figure 5 Role of MK2 Suppression in RSV Infection (A) Representative western blot analysis of MK2 and MK3 expression in A549 cells transfected with 10 nM miRNA mimics, siMK2, siMK3, or controls for 48 hr. Cells were subsequently infected with RSV-A2 at MOI 3 for 24 hr. (B and C) Quantitative analysis of (B) MK2 or (C) MK3 total protein levels in RSV infection normalized to GAPDH shown as the mean ± SEM of n = 4. (D) RSV viral titers are shown as the mean ± SEM of n = 3. Significant differences between RISC-free siRNA control and miRNA or siRNA treatments are indicated (*p < 0.05, **p < 0.01, and ****p < 0.0001, one-way ANOVA). Molecular Therapy - Nucleic Acids 2017 7, 256-266DOI: (10.1016/j.omtn.2017.03.008) Copyright © 2017 The Authors Terms and Conditions